


# Product Data Sheet

## MK 0893

<b>Cat. No.:</b>	A3608
<b>CAS No.:</b>	870823-12-4
<b>Formula:</b>	C32H27Cl2N3O4
<b>M.Wt:</b>	588.48
<b>Synonyms:</b>	MK0893; MK-0893
<b>Target:</b>	GPCR/G protein
<b>Pathway:</b>	Glucagon Receptor
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

≥24.05 mg/mL in DMSO; insoluble in H<sub>2</sub>O; ≥4.8 mg/mL in EtOH with gentle warming and ultrasonic

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	1.6993 mL	8.4965 mL	16.9929 mL
	<b>5 mM</b>	0.3399 mL	1.6993 mL	3.3986 mL
	<b>10 mM</b>	0.1699 mL	0.8496 mL	1.6993 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

Glucagon receptor/IGF-1R antagonist

IC<sub>50</sub> & Target

6.6 nM (glucagon receptor), 6 nM (IGF-1R)

In Vitro

### Cell Viability Assay

Cell Line:	CHO cells expressing the hGCGR.
Preparation method:	Dissolved in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	56-1000 nM; 30 min.

	Applications:	In CHO cells expressing the hGCGR, MK 0893 dose dependently rightshifts the EC50 of glucagon without changing the maximum effect of glucagon. MK 0893 inhibits cAMP production.
In Vivo	<b>Animal experiment</b>	
	Animal models:	hGCGR ob/ob mice.
	Dosage form:	3, 10, and 30 mpk; 1 h; administered orally.
	Applications:	MK 0893 reduces glucose elevation stimulated by glucagon (15 µg/kg) by 30%, 56%, and 81% at 3, 10, and 30 mpk, respectively.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Xiong Y, Guo J, Candelore MR, et al. Discovery of a novel glucagon receptor antagonist N-[(4-((1S)-1-[3-(3,5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl)phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. *J Med Chem*, 2012, 55(13): 6137-6148.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



---

# APEx<sup>x</sup>BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

